DocMorris AG (ZRSEF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
DocMorris AG (ZRSEF) trades at $10.24 with AI Score 41/100 (Grade C). DocMorris AG operates a dual business model encompassing e-commerce pharmacies and a wholesale distribution network for medical and pharmaceutical goods across Switzerland and… Market cap: $500M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for ZRSEF: ZRSEF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ZRSEF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ZRSEF: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
DocMorris AG (ZRSEF) Healthcare & Pipeline Overview
DocMorris AG, a Swiss-based healthcare enterprise, integrates e-commerce pharmacies with a wholesale distribution network for medical and pharmaceutical goods. Operating under brands like DocMorris and Zur Rose, it serves consumers, medical professionals, and online pharmacies across Switzerland and internationally, focusing on consumer health, beauty, and medication management.
What Is the Investment Thesis for ZRSEF?
DocMorris AG presents an investment profile characterized by its strategic dual business model, integrating e-commerce pharmacies with a robust wholesale distribution network for medical and pharmaceutical goods. A core value driver is its established brand recognition within the German-speaking market, which provides a significant competitive advantage in customer acquisition and retention. The company's diverse offerings, including consumer health, beauty, personal care, and medication management services, position it to capitalize on the growing demand for convenient and comprehensive healthcare solutions. Key growth catalysts include the ongoing expansion of e-commerce penetration across Europe, particularly as digital healthcare adoption accelerates, and the potential for increased utilization of its digital health services like TeleClinic. Leveraging its existing distribution infrastructure to reach new markets and optimize supply chain efficiencies also represents a substantial opportunity. However, the investment thesis is tempered by significant risks, notably the company's current unprofitability, evidenced by a -12.0% profit margin, and its high market volatility with a Beta of 1.86. Furthermore, the evolving regulatory landscape surrounding online pharmacies and prescription drug dispensing in various European countries poses an ongoing challenge that requires close monitoring, alongside intense competitive pressures within the sector.
Based on FMP financials and quantitative analysis
ZRSEF Key Highlights
Market Capitalization of $500M, reflecting its current valuation in the public market.
- A negative Profit Margin of -12.0%, indicating the company is currently operating at a loss.
- Gross Margin of 9.4%, which measures the percentage of revenue left after deducting the cost of goods sold.
- A Beta of 1.86, suggesting the stock is significantly more volatile than the overall market.
- Operates a dual business model encompassing both e-commerce pharmacies and a wholesale distribution network for medical and pharmaceutical goods.
Who Are ZRSEF's Competitors?
ZRSEF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARRJF Arjo AB (publ) | $2.91 | +0.00% | $793M | 43 |
| IUSDF AS ONE Corporation | $14.00 | +0.00% | $998M | 46 |
| OMI Owens & Minor, Inc. | $2.68 | +8.94% | $207M | 44 |
| MEDOF Medios AG | $50.00 | +0.00% | $1.28B | 45 |
| GRDN Guardian Pharmacy Services, Inc. | $37.48 | -1.29% | $2.37B | 96 |
| PBH Prestige Consumer Healthcare Inc. | $50.52 | -2.24% | $2.39B | 64 |
| ALFRY Alfresa Holdings Corporation | $13.55 | +0.00% | $2.46B | 49 |
| ACH Accendra Health, Inc. (ACH) is a healthcare solutions company providing products and services to healthcare providers and patients. The company | $1.31 | -0.76% | $100M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ZRSEF's Key Strengths?
Established brand recognition in the German-speaking market.
- Dual business model combining e-commerce pharmacies and wholesale distribution.
- Diverse product and service offerings, including consumer health and medication management.
- Presence of physical pharmacy locations complementing online operations.
What Are ZRSEF's Weaknesses?
Current unprofitability with a negative profit margin of -12.0%.
- High market volatility indicated by a Beta of 1.86.
- Reliance on evolving and potentially restrictive regulatory frameworks in Europe.
- Gross margin of 9.4% may indicate pricing pressures or high cost of goods.
What Could Drive ZRSEF Stock Higher?
ZRSEF catalyst: Potential for regulatory clarity or favorable legislative changes in key European markets regarding online prescription drug dispensing, which could streamline operations and expand market access.
- Successful expansion of DocMorris AG's e-commerce penetration into new geographic regions or demographic segments within Europe, driving increased customer acquisition and sales volume.
- Enhanced integration and adoption of digital health services, such as TeleClinic, leading to diversified revenue streams and stronger customer engagement.
- Strategic optimization of the wholesale distribution network, resulting in improved operational efficiencies and expanded market reach for medical and pharmaceutical goods.
What Are the Key Risks for ZRSEF?
Financial-distress signal — its Altman Z-Score of 1.56 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-32.8%) — the business is not currently generating profit on shareholder capital.
- Evolving and potentially restrictive regulatory landscape for online pharmacies and prescription drug dispensing across various European countries, which could impact business models and market access.
- Intense competitive pressures within the online pharmacy and medical distribution sectors, potentially leading to pricing pressures and reduced market share.
- Sustained negative profit margins of -12.0% could hinder long-term profitability, capital reinvestment, and financial stability if not addressed through operational improvements or revenue growth.
- High market volatility, as indicated by a Beta of 1.86, suggests that the stock price may experience larger swings compared to the broader market, increasing investment risk.
- Challenges in maintaining brand recognition and customer loyalty amidst a rapidly changing digital healthcare environment and aggressive marketing by competitors.
What Are the Growth Opportunities for ZRSEF?
- E-commerce Expansion in European Markets: DocMorris AG has a significant opportunity to further penetrate the European e-commerce pharmacy market, which is projected to grow substantially as digital adoption increases. By leveraging its established brand recognition, particularly in the German-speaking region, and optimizing its online platforms, the company can capture a larger share of the growing online prescription and over-the-counter medication market. This expansion involves enhancing user experience, broadening product assortments, and potentially entering new geographic territories within Europe where online pharmacy penetration is still nascent but poised for growth, thereby increasing its customer base and sales volumes over the next 3-5 years.
- Integration and Expansion of Digital Health Services: The company's TeleClinic brand and focus on medication management services represent a strong growth avenue. As healthcare systems increasingly embrace telemedicine and digital health solutions, DocMorris AG can expand its offerings to include more comprehensive virtual consultations, personalized health programs, and advanced medication adherence tools. This strategic move aligns with broader industry trends towards integrated digital healthcare ecosystems, potentially creating new revenue streams and enhancing customer loyalty by providing holistic health support beyond just product delivery. The market for digital health services is expanding rapidly, offering long-term growth potential.
- Optimization and Expansion of Wholesale Distribution Network: DocMorris AG's wholesale distribution network for medical and pharmaceutical goods offers a robust platform for growth. By optimizing logistics, enhancing supply chain efficiencies, and expanding its network reach, the company can increase its market share in the B2B segment. This involves forging new partnerships with medical professionals and other pharmacies, potentially extending its distribution services to a wider range of healthcare providers. Improving the efficiency and scale of this network can lead to higher volume sales and improved gross margins, particularly as demand for reliable and timely medical supply distribution remains critical across the healthcare industry over the next 2-4 years.
- Diversification of Consumer Health and Beauty Portfolio: The company's offerings in consumer health, beauty, and personal care items represent a significant opportunity for market share expansion. By identifying emerging trends in wellness, natural products, and specialized care, DocMorris AG can strategically expand its product portfolio to meet evolving consumer demands. This diversification can attract new customer segments and increase the average order value from existing customers. Leveraging its e-commerce platform for targeted marketing and product launches can accelerate growth in these high-margin categories, capitalizing on the robust and continuously expanding global consumer health market over the next 1-3 years.
- Strategic Partnerships and Acquisitions: To accelerate growth and enhance market positioning, DocMorris AG can pursue strategic partnerships or targeted acquisitions. Collaborating with technology providers could bolster its digital health platform capabilities, while acquiring smaller, innovative online pharmacies or specialized distribution companies could expand its geographic reach or product offerings. Such inorganic growth strategies can provide access to new customer bases, intellectual property, or operational efficiencies, allowing the company to consolidate its position in fragmented markets. These initiatives, typically evaluated on a case-by-case basis, could yield significant market share gains and synergistic benefits over the next 3-5 years.
What Threats Does ZRSEF Face?
- Ongoing and potential changes in regulations impacting online pharmacies and prescription drug dispensing.
- Intense competitive pressures from both traditional and online pharmacy players.
- Economic downturns or shifts in consumer spending on discretionary health and beauty items.
- Supply chain disruptions affecting the availability and cost of pharmaceutical goods.
What Are ZRSEF's Competitive Advantages?
- Established brand recognition within the German-speaking market, fostering customer trust and loyalty.
- A unique dual business model combining e-commerce pharmacies with a robust wholesale distribution network, offering diversified revenue streams and market reach.
- An extensive and efficient distribution network capable of delivering medical and pharmaceutical goods across Switzerland and internationally.
- A diverse portfolio of products and services, including consumer health, beauty, personal care, and medication management, catering to a broad spectrum of healthcare needs.
What Does ZRSEF Do?
DocMorris AG, originally established as Zur Rose AG in 1993, has evolved significantly, undergoing a name change to Zur Rose Group AG in May 2015 before adopting its current designation. Headquartered in Frauenfeld, Switzerland, the company operates a comprehensive dual business model that strategically combines the reach of e-commerce pharmacies with a robust wholesale distribution network for a diverse array of medical and pharmaceutical goods. Its extensive market footprint spans both within Switzerland and across various international borders, positioning it as a key player in the European healthcare distribution landscape. The company's product and service portfolio is broad, encompassing essential consumer health products, beauty and personal care items, and specialized services focused on efficient medication management. This multi-faceted approach allows DocMorris AG to cater to a wide spectrum of healthcare needs, from daily wellness to chronic condition management. DocMorris AG directly supplies its comprehensive range of products to a diverse client base, including individual consumers through its online mail-order pharmacies and physical pharmacy locations, as well as medical professionals and other online pharmacies. This direct-to-consumer and business-to-business model is supported by several distinct and recognized brands, such as Zur Rose, PromoFarma, TeleClinic, and DocMorris, each contributing to the company's overall market presence and brand equity. The strategic integration of physical pharmacy locations further enhances its accessibility and service delivery capabilities, providing a hybrid model that combines digital convenience with traditional healthcare access. The company's operational strategy leverages its established brand recognition, particularly within the German-speaking market, to drive customer acquisition and retention in a competitive environment. Its commitment to innovation in healthcare delivery is evident in its focus on digital solutions for medication management and its e-commerce platform's continuous enhancement. By maintaining a strong presence in both the digital and physical realms, DocMorris AG aims to provide seamless and integrated healthcare solutions, adapting to the evolving demands of modern consumers and healthcare providers. This integrated approach, from product sourcing and distribution to direct consumer engagement and specialized services, underpins DocMorris AG's strategic position in the dynamic European healthcare sector.
What Products and Services Does ZRSEF Offer?
- Operate e-commerce pharmacies for prescription and over-the-counter medications.
- Manage a wholesale distribution network for medical and pharmaceutical goods.
- Offer a wide range of consumer health, beauty, and personal care items.
- Provide specialized services focused on medication management.
- Maintain physical pharmacy locations to complement their online presence.
- Supply products directly to individual consumers through online mail-order and physical stores.
- Distribute goods to medical professionals and other online mail-order pharmacies.
- Utilize a portfolio of brands including Zur Rose, PromoFarma, TeleClinic, and DocMorris.
How Does ZRSEF Make Money?
- Generates revenue through direct-to-consumer sales of prescription and over-the-counter medications via its e-commerce platforms and physical pharmacies.
- Earns income from the sale of consumer health, beauty, and personal care products to individual customers.
- Secures revenue from the wholesale distribution of medical and pharmaceutical goods to medical professionals and other online mail-order pharmacies.
- Derives income from providing specialized medication management services.
What Industry Does ZRSEF Operate In?
DocMorris AG operates within the dynamic and rapidly evolving Medical - Distribution industry, specifically carving out a significant niche in the online pharmacy and wholesale healthcare goods sectors across Europe. The broader healthcare sector is currently experiencing a profound shift towards digitalization, with increasing consumer preference for convenient, accessible online services for medication and health products. This trend is a primary driver for companies like DocMorris AG, which are well-positioned with established e-commerce platforms. The competitive landscape is characterized by both traditional brick-and-mortar pharmacies adapting to digital channels and pure-play online pharmacy competitors. DocMorris AG differentiates itself through its dual business model, combining direct-to-consumer online sales with a robust wholesale distribution network, and its established brand presence in key European markets. However, the industry faces ongoing challenges related to evolving regulatory frameworks for online prescription dispensing and data privacy, which can significantly impact operational strategies and market expansion.
Who Are ZRSEF's Key Customers?
- Individual consumers seeking prescription and over-the-counter medications, as well as health and beauty products.
- Medical professionals requiring wholesale distribution of pharmaceutical goods.
- Other online mail-order pharmacies sourcing medical and pharmaceutical products.
Forward Outlook
Wall Street analysts project DocMorris AG revenue of about $1.23B for fiscal 2026, with EPS near $-1.69. The estimate reflects 7 contributing analysts.
Financial Health
DocMorris AG's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.56 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for DocMorris AG stands at -32.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -16.2%, showing how much profit it generates from its asset base. Its free cash flow yield is 7.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.87 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -25.0%, the inverse of the P/E and a quick read on earnings relative to price.
DocMorris AG (ZRSEF) Valuation Context
Valued at $500M, ZRSEF is classified as a small-cap stock. Relative to its peer group, ZRSEF's quantitative score of 41/100 is below the peer average of 55/100.
Company Profile
DocMorris AG operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Frauenfeld, CH. The company is led by CEO Walter Hess. ZRSEF has traded publicly since 2018.
ZRSEF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Established brand recognition in the German-speaking market.
- Dual business model combining e-commerce pharmacies and wholesale distribution.
- Diverse product and service offerings, including consumer health and medication management.
- Presence of physical pharmacy locations complementing online operations.
Bear Case
- Current unprofitability with a negative profit margin of -12.0%.
- High market volatility indicated by a Beta of 1.86.
- Reliance on evolving and potentially restrictive regulatory frameworks in Europe.
- Gross margin of 9.4% may indicate pricing pressures or high cost of goods.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
ZRSEF Latest News
No recent news available for ZRSEF.
ZRSEF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ZRSEF.
Price Targets
Wall Street price target analysis for ZRSEF.
ZRSEF MoonshotScore
What does this score mean?
The MoonshotScore rates ZRSEF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Walter Hess
Unknown
Walter Hess serves as the managing leader for DocMorris AG, overseeing an employee base of 1454 individuals. Specific details regarding his educational background, prior career history, and previous leadership roles are not provided in the available source data. His tenure is marked by his current leadership of a significant workforce within the complex and evolving European healthcare distribution and online pharmacy sector, guiding the company's strategic direction and operational execution.
Track Record: Key achievements, strategic decisions, and specific company milestones under Walter Hess's leadership are not detailed in the provided source information. His track record is currently defined by his role in managing the company's dual business model across e-commerce and wholesale distribution, navigating the challenges and opportunities within the European online pharmacy market. The company's strategic focus on established brands and diverse offerings continues under his guidance.
ZRSEF OTC Market Information
DocMorris AG (ZRSEF) trades on the 'OTC Other' tier of the OTC market. This tier is typically for companies that do not meet the disclosure requirements for OTCQX or OTCQB, or choose not to provide financial information to OTC Markets Group. While it is not a direct indicator of company quality, it implies a lower level of public disclosure and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should be aware that companies on this tier may have less readily available financial data and may not be subject to the same stringent reporting standards.
- OTC Tier: OTC Other
- Limited Public Information: The "Unknown" disclosure status means investors may lack comprehensive, timely financial and operational data to make informed decisions.
- Lower Liquidity: Trading on the "OTC Other" tier often results in lower trading volumes and wider bid-ask spreads, making it harder to buy or sell shares at desired prices.
- Lack of Regulatory Oversight: Companies on lower OTC tiers are subject to less stringent regulatory and reporting requirements compared to major exchanges, increasing investment risk.
- Price Volatility: Shares on OTC markets, especially lower tiers, can be highly volatile due to limited information, low liquidity, and speculative trading.
- Difficulty in Valuation: The scarcity of detailed financial disclosures can make it challenging to perform accurate fundamental valuation and assess the company's true financial health.
- Seek out any available financial statements or annual reports directly from the company website or investor relations.
- Investigate news archives and press releases for operational updates, strategic developments, and leadership changes.
- Research any known legal or regulatory actions against the company or its management.
- Assess the company's business model and competitive landscape based on publicly available descriptions.
- Evaluate the management team's background and track record, if any information can be found.
- Consider the company's market capitalization and trading volume as indicators of market interest and liquidity.
- Understand the specific risks associated with the "OTC Other" tier, including disclosure limitations.
- The company is headquartered in Frauenfeld, Switzerland, indicating a physical operational base.
- It was founded in 1993, suggesting a long operational history.
- DocMorris AG operates under several distinct brands, including Zur Rose and DocMorris, indicating established market presence.
- It has a significant employee base of 1454, suggesting a substantial operational scale.
- The company operates a dual business model encompassing both e-commerce pharmacies and a wholesale distribution network.
ZRSEF Healthcare Stock FAQ
What does the AI Score mean for ZRSEF?
ZRSEF holds an AI Score of 41/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. DocMorris AG operates a dual business model encompassing e-commerce pharmacies and a wholesale distribution network for medical and pharmaceutical goods across Switzerland and internationally. …
What does DocMorris AG do?
DocMorris AG, headquartered in Frauenfeld, Switzerland, operates a comprehensive dual business model within the healthcare sector. The company manages both e-commerce pharmacies, offering a wide range of prescription and over-the-counter medications, and a robust wholesale distribution network for medical and pharmaceutical goods. Its market reach extends across Switzerland and internationally, serving individual consumers, medical professionals, and other online mail-order pharmacies.
How does DocMorris AG navigate regulatory challenges in the European online pharmacy market?
DocMorris AG operates in a highly regulated environment, particularly concerning online pharmacies and prescription drug dispensing across various European countries. While specific details on its regulatory navigation strategy are not provided in the source data, the company's continued operation and established market presence suggest an ongoing adaptation to these evolving frameworks.
What are the key growth opportunities for ZRSEF in healthcare?
DocMorris AG's primary growth opportunities in the healthcare sector stem from the increasing digitalization of health services and the expansion of its core business models. One significant avenue is the further penetration of the European e-commerce pharmacy market, leveraging its established brand and infrastructure to capture a larger share of online prescription and over-the-counter medication sales.
What are the main risks for ZRSEF?
DocMorris AG faces several significant risks that investors should monitor. A primary concern is the ongoing evolution of regulatory frameworks governing online pharmacies and prescription drug dispensing across different European countries. Changes in these regulations could impose new operational constraints, increase compliance costs, or limit market access.
What are the key factors to evaluate for ZRSEF?
DocMorris AG (ZRSEF) holds an AI score of 41/100 (low). DocMorris AG presents an investment profile characterized by its strategic dual business model, integrating e-commerce pharmacies with a robust wholesale distribution network for medical and pharmaceutical goods. Not financial advice.
How frequently does ZRSEF data refresh on this page?
ZRSEF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ZRSEF's recent stock price performance?
DocMorris AG (ZRSEF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brand recognition in the German-speaking market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZRSEF overvalued or undervalued right now?
DocMorris AG (ZRSEF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on provided source data; no external research was conducted.